Insights
Resources & News
New shores: The shift from just selling pills to developing value-added services has only just begun
The case for ‘beyond the pill’ services is becoming well established. Most new drugs coming to market are perceived by some to have relatively limited value in their own right (eg incremental benefits over existing options). Some of the most urgent unmet needs in...
Making the Switch: Loyalty strategies are much easier to implement in the OTC segment making switching an attractive option for pharma
The pharmaceutical business model has been in transition for several years. Previously, unique positioning was achieved through clinical differentiation protected by a patent. Payers guaranteed reimbursement even if clinical profiles did not substantially differ from...
The Global Medtech Industry: Visions in Times of Change
The healthcare environment has been transforming faster during the last couple of years. New approaches for managing, financing and competing in healthcare are pushing all players in the sector to constantly question the relevance of their formula for past success. As...
Valuable collection: What are the prospects for grouping complementary services around a product?
In the PME article, ‘If the Shoe Fits’, four emerging pharmaceutical market strategies were identified, based on uniqueness of positioning and type of competition (www. pmlive.com/ shoefits). This next article in the series concentrates on the bottom right quadrant of...
Contract research – Deriving strategic value from emerging markets
Global pharmaceutical companies are re-looking at their R&D processes in order to leverage the opportunity presented by emerging economies, such as India, in contract research. Besides offering the opportunity to save costs tactically in the short term, this is...
Contract Research – Deriving Strategic Value from Emerging Markets
Globally pharmaceutical companies are under immense pressure, with existing lobally pharmaceutical business models under threat. The growth is expected to taper off in the US and other developed countries, while emerging economies are expected to drive a large part of...
Potential to grow: A true understanding of the challenges of niche markets is needed for companies to achieve worthwile returns
For a long time, the pharmaceutical industry was not required to prove superior outcomes to generate large surpluses: companies were paid above the amount required to sustain the economic viability of their product portfolio. Today, severe pressure on healthcare...
Introduction of SwissDRG – upheavals in hospital purchasing require… …new strategies for medical technology providers
Thanks to its international experience, the Swiss medical technology sector is well aware of the latest developments in the healthcare market, especially as smaller companies also tend to work the European markets bordering Switzerland intensively and directly. In the...
If the shoe fits: Pharma needs to put its best foot forward and use the range of tactical responses at its disposal to meet payers’ demands
Despite what we are asked to believe, pharmaceutical marketers used to have it easy. Marketing predominantly to doctors, companies positioned their patent protected drug against competitive products, seeking any meaningful differentiation to drive market share (or...
Insights
Weekly Free Business Resources
If you want to receive weekly business resources and news, please subscribe to our Insights blog.
Almasan AG
The right support for the pharma/ biotech, medtech/ diagnostics, life sciences and healthcare sectors at the right time in the right way: Advisory, Interim Management and Contracting/ Outsourcing.